Abstract

PurposeTo compare two aflibercept treatment regimens and the electrophysiological outcome concerning cone and rod function in age-related macular degeneration (nAMD) over 18 months.Methods41 patients with treatment-naïve nAMD were randomized 1:1 to either arm 1 or 2. Arm 1 received three consecutive monthly aflibercept injections, followed by bimonthly treatment until week 52. Thereafter, a treat-and-extend (TAE) regimen was applied. Arm 2 was treated according to a TAE protocol throughout the 18-month follow-up. We assessed visual acuity (VA), central retinal thickness (CRT), injection rate and interval, and evaluated cone and rod function with full-field and multifocal electroretinography (ffERG, mERG).ResultsThere were no statistically significant differences in mean baseline VA, lesion type, age, gender, or symptom duration between the two arms. During the 18-month follow-up, mean VA improved in arm 1 (n = 19) from 63.5 ± 10.5 to 69.1 ± 9.2 letters; p = 0.098; and in arm 2 (n = 20) from 66.8 ± 13.6 to 73.9 ± 9.0 letters; p = .002. In both arms, mean CRT was significantly reduced; p < 0.000. At month 18, we found no significant difference in the number of injections or injection intervals between groups. Arm 1 had received 11.3 ± 1.7 injections vs. 10.9 ± 2.0 in arm 2. The mean injection interval was 9.2 ± 3.4 weeks vs. 9.5 ± 3.1, with 52% (n = 10) on the maximum 12-week interval in arm 1, and 50% (n = 10) in arm 2. The combined rod-cone a-wave amplitude significantly decreased over time; p = 0.043. The isolated rod b-wave amplitude showed a statistically significant decline; p = 0.026. The overall mERG amplitude and implicit time remained unchanged over time; p = 0.878 vs. p = 0.922. The central ring 1 mERG amplitude improved; p = 0.041, with an unaffected implicit time.ConclusionsAfter 18 months, both treatments arms have received a similar number of injections at comparable intervals. Electrophysiological evaluation shows no signs of toxicity concerning cone function. But ffERGs for the combined and isolated rod response have declined, possibly reflecting either toxic effects of the drug to rods or the natural course of the disease itself.

Highlights

  • Age-related macular degeneration (AMD) presents a leading cause of severe visual loss in the elderly population in developed countries

  • For the entire group of patients in arm 1 and arm 2, Full-field electroretinography (ffERG) selective cone responses and Multifocal electroretinography (mERG) results are stable during the 18-month follow-up, showing no signs of toxic effects on cones in the macula or retinal periphery, Figs. 5 and 6

  • Our study demonstrates a slight improvement in the mERG amplitude for the innermost inner, ring 1, but no significant change in the amplitudes of rings 2–5

Read more

Summary

Introduction

Age-related macular degeneration (AMD) presents a leading cause of severe visual loss in the elderly population in developed countries. There are different treatment regimens, such as monthly evaluation with as-needed injections secondary to signs of activity; pro re nata (PRN). Another widely approved treatment regimen is treatand-extend (TAE), a more proactive regimen with an injection administered at each visit. The treatment interval is extended if there are no longer signs of activity, and reduced in case of recurrence. TAE is considered effective as monthly treatment and superior to PRN by reducing the number of injections and visits, and improving visual acuity outcome and persistence of treatment [4]

Objectives
Methods
Results
Conclusion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call